UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. )*

Calypte Biomedical Corporation

(Name of Issuer)

Common Stock $.001 Par Value

(Title of Class of Securities)

131722100

(CUSIP Number)

Anthony L.M. Inder Rieden
Camden International, Ltd.
Charlotte House, Charlotte Street P.O. Box N9204
Nassau, Bahamas
242-325-1033

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

July 10, 2002

(Date of Event which Requires Filling of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1 (f) or 240.13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D
CUSIP No. 131722100

	1.	Names of Reporting Persons. Anthony L.M. Inder Rieden I.R.S. Identification No. 000-00-0000

	2.	Check the Appropriate Box if a Member of a Group* (a.) [ ] (b.) [ ]

	3.	SEC USE ONLY

	4.	Source of Funds* PF

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to items 2(d) or 2(e) [ ]

6. Citizenship or Place of Organization
United States

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With 7. Sole Voting Power
4,324,490

8. Shared Voting Power
n/a

9. Sole Dispositive Power
4,324,490

10. Shared Dispositive Power
n/a

11. Aggregate Amount Beneficially Owned by Each Reporting Person
5,624,490

12. Check if the Aggregate Amount Represented by Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]

13. Percent of Class Represented by Amount in Row (11)

14. Type of Reporting Person
IN

Item 1. Security and Issuer The securities to which this statemetn relates are shares of the class A Common Stock, $.001 par value (the "common stock"), of Calypte Biomedical Corporation. Principle executive offices of the Corporation are located at 1265 Harbor Bay Parkway Alameda, California 94502.

Item 2. Identity and Background.

(a)	Name: Camden International, Ltd.

(b)	Residence or business address: Charlotte House, Charlotte Street P.O. Box N9204 Nassau, Bahamas

(c)	Present Principal Occupation or Employment: Investment Manager

(d)	Criminal Conviction: n/a

(e)	Court or Administrative Proceedings: n/a

(f)	Citizenship: United States

Item 3. Source and Amount of Funds or Other Consideration: 5,624,490 of the issuer's shares were purchased for cash ($200,000).

Item 4. Purpose of Transaction State the purpose or purposes of the acquisition of securities of the issuer. Describe any plans or proposals which the reporting persons may have which relate to or would result in:
See Item 3. This party has no plans or proposals which relates to or would result in any action specified in clauses (a) through (h) of Item 4 of Schedule 13D.
3
(a)	The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;
n/a
(b)	An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;
n/a
(c)	A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;
n/a
(d)	Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
n/a
(e)	Any material change in the present capitalization or dividend policy of the issuer;
n/a
(f)	Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;
n/a
(g)	Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;
n/a
(h)	Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
n/a
(i)	A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or
n/a
(j)	Any action similar to any of those enumerated above.
n/a


Item 5. Interest in Securities of the Issuer.

(a)	Ownership of 5.1% of Class A Common Stock of the Company.

(b)	i) sole power to vote or to direct the vote = 4,324,490 shares ii) shared power to vote or to direct the vote = none iii) sole power to dispose or to direct the disposition of = 4,324,490 iv) shared power to dispose or to direct the disposition of = none

(c)	n/a


(d)	n/a

(e)	n/a

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. n/a
4

Item 7. Material to be Filed as Exhibits. n/a

Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 29, 2002
	By:	/s/ Anthony L.M. Inder Rieden Anthony L.M. Inder Rieden
	Title:		President


5

CAMDEN INTERNATIONAL LTD SC 13D